Published in J Control Release on December 10, 2004
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release (2008) 2.63
Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm (2010) 1.36
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) (2009) 1.24
Transport across the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther (2010) 1.01
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97
Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugates. ACS Nano (2012) 0.96
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J Control Release (2008) 0.92
A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release (2013) 0.92
Ultrasonic-activated micellar drug delivery for cancer treatment. J Pharm Sci (2009) 0.85
In vitro trafficking and efficacy of core-shell nanostructures for treating intracellular Salmonella infections. Antimicrob Agents Chemother (2009) 0.84
Structural parameters governing activity of Pluronic triblock copolymers in hyperthermia cancer therapy. Int J Hyperthermia (2011) 0.80
Docetaxel-loaded pluronic p123 polymeric micelles: in vitro and in vivo evaluation. Int J Mol Sci (2011) 0.80
Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers. Int J Radiat Biol (2013) 0.79
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J Pharm Sci (2009) 0.77
Brain delivery of proteins via their fatty acid and block copolymer modifications. J Drug Target (2013) 0.77
Degradation kinetics of stabilized Pluronic micelles under the action of ultrasound. J Control Release (2009) 0.77
Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells. J Neuroimmune Pharmacol (2008) 0.76
Cancer Theranostic Nanoparticles Self-Assembled from Amphiphilic Small Molecules with Equilibrium Shift-Induced Renal Clearance. Theranostics (2016) 0.76
Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression. Theranostics (2017) 0.75
The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity (2008) 7.60
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release (2002) 2.68
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release (2008) 2.63
Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev (2002) 2.19
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol (2015) 2.01
Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem (2004) 1.94
Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev (2002) 1.94
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93
Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst (2002) 1.77
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther (2003) 1.61
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine (2002) 1.56
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther (2009) 1.56
Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Release (2005) 1.52
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42
Polymer micelle with cross-linked ionic core. J Am Chem Soc (2005) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Drug efflux transporters in the CNS. Adv Drug Deliv Rev (2003) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Negative regulation of MDA5- but not RIG-I-mediated innate antiviral signaling by the dihydroxyacetone kinase. Proc Natl Acad Sci U S A (2007) 1.35
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem (2008) 1.33
Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med (2002) 1.32
Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem (2008) 1.31
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J Mol Cell Biol (2011) 1.28
Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J Control Release (2006) 1.28
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Design and formulation of polyplexes based on pluronic-polyethyleneimine conjugates for gene transfer. Bioconjug Chem (2002) 1.25
Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response. J Biol Chem (2010) 1.25
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther (2012) 1.25
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials (2011) 1.21
Genomic and proteomic analyses of the terminally redundant genome of the Pseudomonas aeruginosa phage PaP1: establishment of genus PaP1-like phages. PLoS One (2013) 1.20
An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release (2003) 1.19
The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials (2008) 1.19
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials (2009) 1.17
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17
Neural mechanism of intertemporal choice: from discounting future gains to future losses. Brain Res (2009) 1.17
Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release (2005) 1.16
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials (2010) 1.16
Osterix overexpression in mesenchymal stem cells stimulates healing of critical-sized defects in murine calvarial bone. Tissue Eng (2007) 1.14
Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos (2012) 1.13
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release (2009) 1.11
Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug Chem (2005) 1.11
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine (2011) 1.11
Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release (2009) 1.11
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci (2011) 1.10
So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Curr Opin Immunol (2002) 1.09
Polymeric micelles with ionic cores containing biodegradable cross-links for delivery of chemotherapeutic agents. Biomacromolecules (2010) 1.09
WDR5 is essential for assembly of the VISA-associated signaling complex and virus-triggered IRF3 and NF-kappaB activation. Proc Natl Acad Sci U S A (2009) 1.08
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol (2003) 1.08
Poly(2-oxazoline)s as polymer therapeutics. Macromol Rapid Commun (2012) 1.07
Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res (2004) 1.07
Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol (2008) 1.07
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic Biol Med (2010) 1.06
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos (2007) 1.06
Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm (2006) 1.05
The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials (2010) 1.04
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. Mol Pharm (2012) 1.03
Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release (2010) 1.03